Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...
With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...
MedPage Today on MSN
Targeted Duo Wins Again in BRAF-Mutant Colorectal Cancer
SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...
Pfizer Inc. (NYSE:PFE) is one of the best affordable stocks under $30. Pfizer Inc. (NYSE:PFE) announced on January 10 ...
A groundbreaking study is providing new hope for patients with advanced or metastatic colon cancer, particularly those with something known as a BRAF V600E mutation, a historically difficult-to-treat ...
Nurix Therapeutics, Inc. presented promising preclinical data at the AACR 2025 Annual Meeting, showcasing their innovative targeted protein degradation medicines aimed at addressing various cancers, ...
Johnson & Johnson (NYSE:JNJ) today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal ...
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback